Centessa Pharmaceuticals Plc Stock Price, News & Analysis

Centessa Pharmaceuticals (CNTA) has outlined its progress in advancing its rare disease and immuno-oncology pipeline toward its '4x24' goal, aiming for four registrational programs in 2024. Key updates include the ongoing registrational ACTION Study for lixivaptan targeting ADPKD and a Phase 1 study for ZF874 in AATD. As of March 31, 2022, Centessa reported cash and cash equivalents of $544.5 million, ensuring operational funding through mid-2024. The first quarter saw R&D expenses of $36.9 million and a net loss attributable to ordinary shareholders of $54.5 million.

Scorpion Therapeutics has appointed Dr. Saurabh Saha to its Board of Directors. Dr. Saha, CEO of Centessa Pharmaceuticals, has over 20 years of experience in biopharmaceutical research. This strategic appointment aligns with Scorpion's Precision Oncology 2.0 strategy, aiming to enhance cancer treatment development. Dr. Saha's expertise is expected to be pivotal as the company prepares for investigational new drug applications for its lead programs in the upcoming year.

Centessa Pharmaceuticals (NASDAQ: CNTA) reported a net loss of $60.8 million for Q4 2021 and $381.1 million for the full year, primarily driven by $220 million in R&D expenses from acquisitions. The company holds $595.1 million in cash as of December 31, 2021, aimed to fund operations into early 2024.

The company focuses on rare diseases and immuno-oncology, with SerpinPC registrational studies planned for Hemophilia B in 2H 2022, and Lixivaptan in a Phase 3 trial for ADPKD. Centessa's '4x24' goal aims for four registrational programs by 2024.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced that CEO Saurabh Saha will present at the Guggenheim Genomic Medicines & Rare Disease Day on March 31, 2022, at 11:00 AM ET. Investors can access the live webcast and archived recordings on the company’s investor relations website.

This presentation aligns with Centessa's mission to develop impactful medicines across various therapeutic areas, including oncology, hematology, and neuroscience. For more details, visit Centessa's website.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced the appointment of Antoine Yver, MD, MSc, as Executive Vice President and Chairman of Development, and Javad Shahidi, MD, MSc, as Chief Medical Officer. Dr. Yver will oversee overall development strategy, while Dr. Shahidi will manage clinical development teams. CEO Saurabh Saha emphasized the recruitment of talent amid plans for registrational trials and entry of multiple assets into clinical phases. Dr. Shahidi's previous role at Daiichi Sankyo involved leading significant oncology programs.

Centessa Pharmaceuticals (Nasdaq: CNTA) and its subsidiary Palladio Biosciences have initiated dosing in the pivotal Phase 3 ACTION Study, evaluating lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD). This trial aims to enroll ~1,350 participants across 200 sites in over 20 countries, with completion expected in H2 2023. Positive results may lead to a New Drug Application (NDA) submission post the double-blind study phase. Lixivaptan's unique profile may mitigate liver toxicity issues associated with existing ADPKD therapies, enhancing its therapeutic potential.

Centessa Pharmaceuticals (CNTA) has initiated the global ACTION Study, a pivotal Phase 3 clinical trial investigating lixivaptan as a treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD). With up to 1,350 subjects, the double-blind trial aims to assess lixivaptan's efficacy in slowing renal function decline over 52 weeks. Initial safety data from four subjects in the ALERT Study show successful titration of lixivaptan without liver toxicity, while a new patent protects lixivaptan use in ADPKD until 2038. The first subject is expected to be dosed in Q1 2022.

Centessa Pharmaceuticals (Nasdaq: CNTA) announced its upcoming addition to the NASDAQ Biotechnology Index, effective December 20, 2021. This index includes companies classified as Biotech or Pharma that meet specified criteria. The announcement reflects Centessa's innovative, asset-centric model aimed at developing impactful medicines across multiple therapeutic areas such as oncology and immunology. This addition may enhance Centessa's visibility and investor interest, potentially influencing its stock performance positively.

IMIDomics Inc. has established its Scientific and Business Advisory Boards to enhance its mission in developing precision medicines for immune-mediated inflammatory diseases (IMIDs) such as lupus and rheumatoid arthritis. The boards consist of leading experts including Dan Littman and Luisa Salter-Cid, aiding IMIDomics in leveraging its Precision Discovery Engine, which integrates extensive clinical data to innovate therapies for IMIDs. CEO Juan Harrison emphasizes the importance of advancing treatment options for these complex and often undertreated conditions.